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Disruption of the BRCA2 tumor suppressor is associ-
ated with structural and numerical chromosomal
defects. The numerical abnormalities in BRCA2-defi-
cient cells may partly result from aberrations in cell
division caused by disruption of BRCA2 during cyto-
kinesis. Here we show that BRCA2 is a component of
the midbody that is recruited through an interaction
with Filamin A actin-binding protein. At the midbody,
BRCA2 influences the recruitment of endosomal
sorting complex required for transport (ESCRT)-
associated proteins, Alix and Tsg101, and formation
of CEP55-Alix and CEP55-Tsg101 complexes during
abscission. Disruption of these BRCA2 interactions
by cancer-associated mutations results in increased
cytokinetic defects but has no effect on BRCA2-
dependent homologous recombination repair of
DNA damage. These findings identify a specific role
for BRCA2 in the regulation of midbody structure
and function, separate from DNA damage repair,
that may explain in part the whole-chromosomal
instability in BRCA2-deficient tumors.
INTRODUCTION
Germline mutations in the BRCA2 breast and ovarian cancer
susceptibility gene result in an increased lifetime risk of breast
and other cancers. Tumors forming in these patients and in
brca2/ mouse models exhibit significant structural and
numerical chromosomal defects. Because BRCA2 is directly
involved in homologous recombination repair of DNA double
strand breaks and interstrand crosslinks, the observed struc-
tural chromosomal alterations are thought to derive from the
absence of RAD51-mediated BRCA2 DNA repair activity. In
contrast, whole-chromosomal defects detected in BRCA2
mutant tumors and deficient cells have been associated with
aberrations in both chromosome segregation and cell division
(Daniels et al., 2004). One explanation for these chromosomal
defects is the presence of BRCA2 at the centrosome throughoutDevethe cell cycle and the involvement of BRCA2 in centrosome
duplication (Wu et al., 2005). Specifically, depletion or inactiva-
tion of BRCA2 results in centrosome amplification, which can
lead to unequal separation of chromosomes during the meta-
phase to anaphase transition (Ganem et al., 2009). BRCA2 has
also been found to localize to the central spindle and midbody
during telophase and cytokinesis, and depletion or inactivation
of BRCA2 has been associated with multinucleation (Daniels
et al., 2004; Jonsdottir et al., 2009; Ryser et al., 2009). Although
the influence of BRCA2 on cytokinesis is not well defined, loss of
BRCA2 activity during this phase of the cell cycle has been impli-
cated in disruption of myosin II organization at the cleavage
furrow and the intercellular bridge. Similarly, disruption of the
interaction between BRCA2 and HMG20b, a kinesin-like coiled
coil protein implicated in G2-M transition has been associated
with defects in the completion of cell division (Lee et al., 2011).
Furthermore, it has been suggested that BRCA2 complexes
with Aurora B, an important regulator of midbody function,
during cytokinesis (Ryser et al., 2009). In contrast one study
based on BRCA2 depletion by siRNA has suggested that
BRCA2 is not localized to the midbody and has no influence
on cytokinesis (Lekomtsev et al., 2010).
Here we confirm that BRCA2 localizes to the central spindle
and midbody during telophase and cytokinesis, and we demon-
strate that absence of BRCA2 from the midbody disrupts local-
ization of several components of the central spindle and the
midbody and impairs cytokinesis. We establish that an inter-
action between BRCA2 and Filamin A is required for the recruit-
ment of BRCA2 to the central spindle and the midbody. In
addition, we provide evidence suggesting that BRCA2 influ-
ences CEP55-dependent midbody localization of endosomal
sorting complex required for transport (ESCRT) complexes that
are required for abscission during the terminal stage of cytoki-
nesis. Furthermore, we identify breast cancer associated muta-
tions in the Filamin A interacting domain of BRCA2 that exclude
BRCA2 from the midbody and mutations in the N-terminal
CEP55, Alix and Tsg101 interacting domains of BRCA2 that
disrupt these interactions and reduce ESCRT complex recruit-
ment to midbody. Thus, disorganization of the midbody caused
by the absence or disruption of BRCA2 may account, in part,
for the numerical chromosomal instability observed in BRCA2-
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BRCA2 Is a Component of the Midbody
To verify that BRCA2 localizes to the spindle midzone during
telophase and the intercellular bridge and midbody during late
abscission (Daniels et al., 2004) we studied the localization of
endogenous BRCA2 in HeLa cells throughout mitosis by immu-
nofluorescence (IF) microscopy. BRCA2 was detected at the
centrosome, the spindle midzone during telophase (Figure 1A),
and at themidbody during abscission and cytokinesis (Figure 1A,
high magnification), coincident with MgcRacGAP, a marker of
the central spindle and the midbody (Figure 1B). The specificity
of antibodies for BRCA2 was verified by an inability to detect
BRCA2 at the centrosome, midzone, or midbody by immunoflu-
orescence in the presence of BRCA2 siRNAs. In addition, quan-
tification of BRCA2 intensity at themidbody and normalization by
adjacent a-tubulin intensity in 293T cells treated with a BRCA2
siRNA pool (Dharmacon), two individual BRCA2 siRNAs
(QIAGEN) and a BRCA2 siRNA scrambled control showed that
both antibodies (Ab-1 and Ab-2) detected much reduced levels
of BRCA2 following BRCA2 depletion by siRNAs (Figure S1A
available online). The Ab-1 antibody also detected BRCA2 at
the midbody, centrosomes and central spindle during mitosis
in pancreatic tumor cells from brca2+/+ but not brca2/ mice
(Figures 1C and S1B). Western blot analysis of the cell extracts
derived from brca2/ and brca2+/+mice confirmed the absence
of BRCA2 from brca2/ cells (Figure S1C). In addition, time-
lapse microscopy of cells expressing EGFP-tagged BRCA2
(WT-BRCA2) and mCherry tagged a-tubulin identified BRCA2
at centrosomes, the spindle midzone, and the midbody until
dissolution of the intercellular bridge and separation of daughter
cells (Figure S1D and Movie S1).
To evaluate possible interactions between BRCA2 and central
spindle and midbody proteins we immunoprecipitated FLAG-
tagged BRCA2 from 293T cells and western blotted for a number
of midbody markers. We verified that BRCA2 formed a complex
with Aurora B (Figure S1E) (Ryser et al., 2009), and showed
that BRCA2 interacted with PRC1 (Figure S1E) and CEP55
(Figure 1D). Characterization of immune complexes from mitotic
HeLa cells confirmed associations between endogenous BRCA2
and components of the central spindle and midbody including
MKLP1, CEP55, and Aurora B (Figures 1D and S1F), which
localize to the midbody and are involved in cytokinesis (Morita
et al., 2007). We also verified a previously described interaction
between BRCA2 and Filamin A (Yuan and Shen, 2001), a com-
ponent of the actomyosin complex, during cytokinesis (Fig-
ure S1G). However, we could not detect any interaction between
BRCA2 and Anillin (Figure 1E), which colocalizes withmyosin II at
the cellular cortex during cleavage furrow formation.
Inactivation or Depletion of BRCA2 Induces a Failure
of Cytokinesis
Given the interaction of BRCA2 with components of the central
spindle and midbody, we further evaluated the influence of
BRCA2 on cytokinesis. Consistent with previous reports of a
failure of cytokinesis in BRCA2-deficient cells (Daniels et al.,
2004; Jonsdottir et al., 2009; Ryser et al., 2009) brca2/murine
pancreatic tumor cells displayed an elevated frequency of unre-
solved cytokinetic bridges and multinucleated cells compared138 Developmental Cell 23, 137–152, July 17, 2012 ª2012 Elsevier Into brca2+/+ cells (Figures 1F and S1H). Similar effects of brca2
deficiency were observed in mouse embryonic fibroblast (MEF)
lines derived from the brca2/ and brca2+/+mice, and in human
BRCA2-deficient PEO1 ovarian cancer cells, relative to sponta-
neously reverted wild-type BRCA2 PEO4 controls (Sakai et al.,
2008, 2009) (Figure 1G). To demonstrate a direct effect of
BRCA2 deficiency on cytokinesis we performed live cell micros-
copy of H2B-mRFP tagged cells derived from the brca2/ and
brca2+/+ mice. We focused on postmetaphase mitotic cells and
categorized cells by normal, delay (>1 hr to progress from
early anaphase to complete abscission), or failure (inability
to complete abscission) of cytokinesis (Movies S2, S3, and
S4). Brca2/ cells displayed significantly greater delay or failure
of cytokinesis than brca2+/+ cells (p = 0.008) (Figure 1H). In addi-
tion, acute depletion of BRCA2 from HeLa cells by siRNA (Fig-
ure S1I) increased delay and failure of cytokinesis relative to
controls (p = 0.004), similarly to the depletion of CEP55
(p = 0.01), a known mediator of cytokinesis (Zhao et al., 2006)
(Figures 1I and S1J).
Next, we evaluated the ability of BRCA2 to rescue the cytoki-
netic defects in BRCA2-deficient cells. Initially we generated a
BRCA2 mini-gene (B2-Ahd1) that eliminated the central
Rad51-binding domains and part of the DNA binding domain
of BRCA2 but retained the N and C termini (Wang et al., 2011;
Yuan and Shen, 2001) (Figure S1K), such that effects on cytoki-
nesis could be studied independently of influences on DNA
damage repair. B2-Ahd1 expressed a 200 kDa protein that
appropriately localized to the centrosome and midbody of
293T cells (Figures S1L and S1M), interacted with midbody
proteins CEP55 and Filamin A (Figure S1N), and exhibited resis-
tance to BRCA2 siRNA depletion (Figure S1M) due to the
absence of the siRNA binding site. Importantly, B2-Ahd1
reduced the frequency of cytokinesis defects in brca2/ cells
similarly to wild-type BRCA2 (Figure S1O). In addition, live cell
imaging of postmetaphase mitotic brca2/ cells (p = 0.001)
and HeLa cells treated with BRCA2 siRNA (p = 0.03) showed
that expression of B2-Ahd1 significantly reduced the cytokinetic
defects associated with BRCA2 absence or depletion (Figures
1H and 1I).
Failure of Cytokinesis in BRCA2-Deficient Cells Is Not
Associated with Chromatin/DNA Bridges
Given these data we postulated that the failure of cytokinesis
associated with BRCA2 deficiency results from disruption of
a specific BRCA2 function at the midbody. However, because
unresolved DNA and chromatin bridges during anaphase and
telophase can induce cytokinesis defects (Steigemann et al.,
2009), DNA segregation abnormalities might contribute to the
cytokinetic defects in BRCA2-deficient cells. Here we adopted
Lap2b (Steigemann et al., 2009) as a marker of unresolved
DNA and chromatin bridges during late abscission, after veri-
fying a significant increase in the frequency of Lap2b staining
chromatin bridges in HeLa cells treated with etoposide
(p = 0.03) to induce segregation defects. No significant differ-
ence in the frequency of Lap2b staining was observed in murine
brca2/ cells relative to brca2+/+ cells (p = 0.86) (Figures S2A
and S2B), in PEO1 BRCA2-deficient cells relative to isogenic
wild-type BRCA2 PEO4 cells (Sakai et al., 2008) (p = 0.81),
and in HeLa cells with and without BRCA2 siRNA treatmentc.
Figure 1. Influence of Midbody-Associated BRCA2 on Cytokinesis
(A) Cellular localization of BRCA2 in mitotic HeLa cells was evaluated by immunofluorescence (IF) staining for BRCA2 and a-tubulin.
(B) IF of HeLa cells for BRCA2 and MgcRacGAP during anaphase and telophase.
(C) IF of brca2+/+ and brca2/ cells for Brca2. Arrows indicate the midbody. Scale bars represent 10 mm (A–C).
(D and E) Immunoblotting (WB) of defined immunoprecipitates (IP) from mitotic HeLa cells for BRCA2, CEP55, and MKLP1 (D), and for BRCA2 and Anillin (E).
(F and G) Quantification of multinucleation and unresolved cytokinetic bridges in brca2+/+ (#1, #2) and brca2/ (#3, #4) tumor cells (F) and PEO1 and PEO4 tumor
cells (G). Error bars represent standard error (SE).
(H) Quantitation (%) of postmetaphase brca2+/+ and brca2/ cells and B2-Adh1 reconstituted brca2/ cells exhibiting normal, failed or delayed (for >1 hr)
cytokinesis.
(I) Quantitation (%) of postmetaphase HeLa cells treated with BRCA2, CEP55 siRNA, or BRCA2 siRNA and B2-Adh1 as in (H). The significance (p-values) of
differences between ratios of combined failed/delayed cytokinesis to normal cytokinesis under various conditions are shown.
See also Figures S1 and S2 and Movies S1, S2, S3, and S4.
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BRCA2 Mutations Result in Failure of Cytokinesis(p = 0.93) (Figures S2A and S2B). Because of the known interac-
tion between BRCA2 and Filamin A, we also evaluated but found
no difference in the frequency of chromatin bridges in human Fil-
amin A-deficient cells and wild-type controls (p = 0.95) (Figures
S2A and S2B). In contrast, elevated levels of unresolved cytoki-
netic bridges were observed in all BRCA2-deficient cells com-
pared to cells expressing wild-type BRCA2.
Because ultrafine DNA bridges (UFBs) are an established
source of cytokinesis defects in certain cells types (Vinciguerra
et al., 2010) we also compared the frequencies of UFBs in
BRCA2-depleted cells, control cells, and FANCA-depleted cells.
Although immunostaining of Bloom’s syndrome protein (BLM)
revealed a high frequency (52%) of UFBs in FANCA-depleted
cells, only 22% of BRCA2-depleted cells and 16% of control
cells displayed UFBs (Figures S2C–S2E). Overall these results
indicate that unresolved UFBs and chromatin bridges do not
account for much of the influence of BRCA2 inactivation/deple-
tion on cytokinesis.
BRCA2 Is Required for Localization of Microtubule-
Associated Proteins to the Midbody
Further characterization of the influence of BRCA2 on the mid-
body by immunofluorescence analysis revealed that BRCA2
deficiency had no effect on the localization of Plk1, Aurora B
(Figure S3A), Eg5, CENP-E, Anillin, F-actin (data not shown),
Filamin A, and CEP55 (Figures 2A and 2B) to the central spindle
and midbody during telophase and cytokinesis. In contrast, and
consistent with previous observations, myosin II was depleted
andmislocalized at the cleavage furrow and the spindle midzone
(Figures 2A and 2B) (Daniels et al., 2004). In addition, the staining
for MKLP1 and MKLP2 during late abscission was disordered
and no longer specific to the midbody ring in brca2/ cells
(Figures 2A and 2B). Defective localization of MKLP1 at the mid-
body ring was highly significantly associated with BRCA2 inacti-
vation (p < 0.001) (Figure 2C). Similarly, PRC1 inappropriately
stained the entire cytokinetic bridge during abscission indicating
an inability of PRC1 to efficiently localize to the midbody in the
absence of BRCA2 (Figure 2B) (Zhao et al., 2006). In contrast,
the absence of BRCA2 had no effect on the localization of
MKLP1, MKLP2, and PRC1 to the central spindle (Figure S3B).
The mislocalization of these markers from the midbody, but
not from the central spindle, suggested a specific role for
BRCA2 in maintaining the structure of the midbody.
The final stage of cytokinesis involves ESCRT-associated
membrane abscission that is mediated, in part, by CEP55 inter-
actions with Alix and Tsg101 (Carlton and Martin-Serrano, 2007;
Morita et al., 2007). Staining for these markers in brca2/ and
brca2+/+ cells identified significant differences in the levels of
both Alix (p < 0.001) and Tsg101 (p < 0.001), when categorized
as prominent, weak, and absent staining at themidbody (Figures
2A–2C). Furthermore, the v-SNARE complex component, Endo-
brevin, that is involved in membrane fission during terminal cyto-
kinesis, was also frequently reduced or absent from themidbody
of brca2/ cells (Figures 2A and 2B). Although CEP55 localiza-
tion to the midbody appeared normal, the mislocalization of Alix,
Tsg101, and Endobrevin was consistent with the effect of CEP55
knockdown on cytokinesis (Zhao et al., 2006), where the mid-
body ring is disrupted, both Tsg101 and Endobrevin are absent
from the midbody (Zhao et al., 2006), and the organization140 Developmental Cell 23, 137–152, July 17, 2012 ª2012 Elsevier Inof midbody microtubules is altered (Matuliene and Kuriyama,
2002). However, BRCA2 deficiency differs from CEP55 defi-
ciency in that Plk1 and Aurora B are absent from the central
spindle and midbody in CEP55-depleted cells (Zhao et al.,
2006), but are present in BRCA2-deficient cells (Figure S3A).
To confirm the mislocalization of midbody markers in the
absence of functional BRCA2 protein, we also assessed
the ability of reconstituted BRCA2 (Figure S3C) to correct the
defective localization of midbody markers in brca2/ cells.
GFP-tagged BRCA2 correctly localized to the centrosome and
midbody during telophase (Figure 2D), relocalized MKLP1 to
the midbody ring (Figure 2E), and relocalized Endobrevin to the
cytokinetic bridge and the midbody (Figure 2F).
Filamin A Mediates BRCA2 Localization to the Midbody
To identify the domain of BRCA2 responsible for localization
to the midbody, the ability of nine overlapping FLAG-tagged
BRCA2 fragments to localize to this structure was evaluated by
immunofluorescence staining (Figure 3A). The BRCA2 F8 frag-
ment containing amino acids 2516–3030 displayed prominent
staining at the spindle midzone and midbody (Figure S3D) and
BRCA2 fragments F2 and F3 displayed weak staining at the mid-
body (Figure S3E). Consistent with the F8 findings, time lapse
microscopy of 293T cells expressing a GFP-tagged C-terminal
BRCA2 fragment (amino acids 2126–3418) detected the
BRCA2 fragment at the central spindle following initiation of
furrow ingression and at the midbody during abscission (Movie
S5). Importantly, the F8 region of BRCA2 contains part of the
BRCA2 DNA binding domain (Yang et al., 2002) and a binding
domain (amino acids 2973–3001) for Filamin A (Yuan and
Shen, 2001) and BCCIPa (Liu et al., 2001).
The Filamin A actin binding protein is associated with the
cleavage furrow (Nunnally et al., 1980), acts as a scaffold for
cytoskeletal and cytokinetic proteins (Playford et al., 2006), is
present at the spindle midzone and the midbody during telo-
phase (Figure 2A), and interacts with both full-length BRCA2
(Figures 3B and S1G) and BRCA2-F8 (Figure 3C). To determine
whether BRCA2 is dependent on Filamin A for localization to
the central spindle and midbody, we depleted Filamin A from
293T cells and from brca2+/+ tumor cells using anti-Filamin A len-
tiviral shRNAs. In the absence of Filamin A, BRCA2was substan-
tially depleted from the spindle midzone and midbody but was
retained at centrosomes (Figures 3D and S4A). In addition,
MKLP1 andMKLP2 displayed disordered localization at themid-
body ring (Figure 3D), PRC1 stained the entire intercellular bridge
(Figure 3D), and the levels of Endobrevin at the midbody were
substantially reduced (Figures 3D and S4A). To exclude the
possibility of off-target shRNA effects, midbody localization of
BRCA2, PRC1, Endobrevin, MgcRacGAP, and Plk1 were as-
sessed in melanoma cells lacking Filamin A (M2/FLNA/) or
stably reconstituted with Filamin A (A7/FLNA+/+) (Cunningham
et al., 1992). In the absence of Filamin A the levels of BRCA2
and Endobrevin at the central spindle and midbody were
substantially reduced (Figure S4B) and PRC1 no longer localized
to the midbody (Figure S4B), whereas, MgcRacGAP and Plk1
localization to the midbody was unaffected (Figure S4C).
Furthermore, FLNA/ cells displayed elevated levels of multinu-
cleation and unresolved cytokinetic bridges similarly to brca2/
cells (Figures S4D and S4E).c.
Figure 2. BRCA2-Dependent Localization of Midbody Markers
(A and B) Localization of midbody markers in brca2/ and brca2+/+ cells by immunofluorescence (IF) staining with antibodies against markers (green) and
a-tubulin (red).
(C) Quantification of proportions of cells from (A and B) displaying defects in localization of markers at the midbody. P-values for differences in proportions of
cells exhibiting defined defects were obtained by Poisson regression analysis.
(D) Reconstitution of GFP-BRCA2 to the centrosomes and midbody of brca2/ mouse tumor cells.
(E and F) IF for MKLP1 (red in E) or Endobrevin (red in F) and a-tubulin (green) in brca2/mouse tumor cells after reconstitution with GFP-BRCA2 (green). Arrows
(B and F) indicate mislocalized markers in brca2/ cells. Scale bars represent 5 mm (A, B, D–F).
See also Figure S3.
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Figure 3. Characterization of the Filamin A Binding Domain of BRCA2
(A) Schematic representations of BRCA2 fragments and the ability (+), inability (), or partial ability (+/) to localize to the midbody. Amino acids positions are
shown in parentheses.
(B) Interaction between BRCA2 and Filamin A. Immunoblotting (WB) for BRCA2 and Filamin A after the indicated IPs from 293T cells expressing FLAG-BRCA2.
(C) Identification of a BRCA2 Filamin A interaction domain by immunoblot (WB) analysis for FLAG and Filamin A in anti-FLAG IPs from 293T cells expressing
FLAG-tagged fragments of BRCA2.
(D) Localization by IF of midbody markers (green) and a-tubulin (red) in 293T cells treated with lentiviral control or FLNA (Filamin A) shRNAs. Scale bar
represents 5 mm.
See also Figure S4 and Movie S5.
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Disrupt Localization to the Midbody
Next we explored the influence of missense mutations in the
Filamin A binding domain of BRCA2 on the interaction with Fila-
min A, localization of BRCA2 to the central spindle andmidbody,
and the integrity of cytokinesis. We selected 12 mutations from
the Filamin A binding site (residues 2970–3020) of BRCA2 for
evaluation, including five mutations (L2972W/R2973C/E3002D/
E3002K/S3020C) from the Breast Cancer Information Core
(BIC) website that lists cancer-associated missense mutations
in the BRCA2 gene identified through clinical genetic screening
of high-risk breast cancer families; six mutations (L2987A/
W2990A/L3000A/G3003A/R3005A/S3016A) in residues fully
conserved between pufferfish (Fugu rubripes) and human; and
one mutation in a nonconserved residue (K3017A) as a control
(Figures 4A and S5A). Full-length FLAG-tagged BRCA2 expres-
sion constructs encoding these missense mutant proteins (Far-
rugia et al., 2008; Wu et al., 2005) were immunoprecipitated
from 293T cells and western blotted for BRCA2 and Filamin A
to assess the ability of each mutation to disrupt the BRCA2-
Filamin A interaction. Of the 12 mutations, E3002K disrupted
the interaction with Filamin A, R3005A substantially reduced
the interaction, and E3002D partially reduced the interaction
(Figures 4A and S5A). Confocal microscopy showed that the
E3002K and R3005A mutants, failed to localize efficiently to
the midbody during abscission (Figure 4B). In contrast, other
mutants that did not influence the interaction with Filamin A,
such as L2987A andW2990A, localized normally to the midbody
(Figure 4B). Live cell imaging of 293T cells expressing GFP-
tagged full-length E3002K BRCA2 also confirmed that this
mutant was unable to localize to the central spindle or the mid-
body (Figure S5B), although the mutant did localize to centro-
somes (Figure S5B and Movie S6).
We then used the E3002K and R3005A mutants to assess the
effect of disrupting the Filamin A-BRCA2 interaction on the local-
ization of central spindle and midbody markers. Neither mutant
excluded Filamin A from the central spindle or the midbody.
However, both mutants disordered localization of MKLP1 and
MKLP2 at the midbody ring and mislocalized PRC1 along the
intercellular bridge during abscission (Figure 4C), but did not
alter the localization of Plk1 and CEP55 to the midbody (Fig-
ure S5C). The mutants also had no influence on the localization
of these markers to the central spindle (data not shown). In addi-
tional studies in brca2/ cells, E3002K and R3005A did not
rescue MKLP1 localization to the midbody ring or reconstitute
Endobrevin at the midbody during abscission (Figure 4D).
Together these findings are consistent with a direct influence
of BRCA2 on the midbody during late abscission that is depen-
dent on recruitment of BRCA2 to the midbody through an inter-
action with Filamin A.
Disruption of the Filamin A Interacting Domain in BRCA2
Causes a Failure of Cytokinesis
To confirm that disruption of the BRCA2-Filamin A interaction
resulted in reduced efficiency of cytokinesis we evaluated the
ability of the BRCA2missensemutants to inducemultinucleation
and unresolved cytokinetic bridges in 293T cells. Immunofluo-
rescence analysis determined that the E3002K and R3005A
mutations, which disrupted the BRCA2-Filamin A interaction,Deveinduced substantially elevated frequencies of unresolved cyto-
kinetic bridges and multinucleated cells, whereas other muta-
tions had no effect (Figure 5A). Likewise, E3002D induced a
moderate increase in multinucleation and cytokinetic bridges,
consistent with the mild effect of this mutation on Filamin A
binding (Figures 4A and 5A). Similar dominant negative effects
on cytokinesis were observed when expressing these mutants
in brca2+/+ cells (Figure 5B). In addition, in contrast to wild-
type BRCA2 reconstitution of BRCA2-deficient cells, the
E3002K and R3005A mutants failed to reduce the frequency of
cytokinetic bridges and multinucleation (Figure 5C). Further-
more, quantitation of chromosome numbers in metaphase
spreads of brca2/ and brca2+/+ cancer cell lines showed that
the E3002K and R3005A mutants increased whole-chromo-
somal instability in brca2+/+ cells and failed to reduce instability
in brca2/ cells similarly to wild-type BRCA2 (Figure 5D),
consistent with a delay or failure of cytokinesis.
Because numerical chromosomal alterations can also result
from multipolar mitoses and merotelic attachment of microtu-
bules following centrosome amplification (Ganem et al., 2009),
we also evaluated the influence of the E3002K and R3005A
variants on centrosome number. Immunofluorescence staining
for centrosomal g-tubulin in brca2+/+ and brca2/ cells express-
ing the FLAG-tagged E3002K or R3005A mutants showed that
both mutants maintained a normal centrosome complement in
brca2+/+ cells and partially rescued centrosome amplification in
brca2/ cells, similarly to wild-type BRCA2 (Farrugia et al.,
2008) (Figure S5D). Thus, the failure of cytokinesis and chro-
mosomal instability induced by disruption of the BRCA2-
Filamin A interaction is independent of an effect on centrosome
duplication.
BRCA2 Function at theMidbody Is Independent of a Role
in DNA Repair
Because the Filamin A binding and midbody localization domain
of BRCA2 overlaps with the homologous recombination (HR)
DNA repair associated DNA binding domain, we assessed
whether disruption of Filamin A binding also disrupted the
homology directed repair (HDR) activity of BRCA2. All mutations
that had no effect on Filamin A binding to BRCA2 reestablished
wild-type HDR activity in BRCA2-deficient V-C8 cells (Figure 5E).
However, the E3002K mutant that disrupted binding and in-
creased the frequency of cytokinetic failure (Figure 5A) failed to
rescue HDR activity, consistent with disruption of the BRCA2
DNA binding domain. Similarly, the E3002D and W2990A
mutants that partially reduced Filamin A binding failed to com-
pletely rescue HDR activity (Figure 5E). In contrast, the BRCA2
R3005Amutation that disrupted Filamin A binding and promoted
failure of cytokinesis successfully corrected HDR activity simi-
larly to wild-type BRCA2 (Figure 5E). Thus, we conclude that
the R3005A mutation in the Filamin A interacting domain of
BRCA2, which overlaps with the DNA binding domain, can
distinguish between the influence of BRCA2 on cytokinesis
and on DNA repair.
BRCA2 Regulates the Presence of CEP55 Signaling
Complexes at the Midbody
Although recruitment of BRCA2 to the midbody is important for
completion of cytokinesis, the mechanisms by which BRCA2lopmental Cell 23, 137–152, July 17, 2012 ª2012 Elsevier Inc. 143
Figure 4. Influence of BRCA2 Missense Mutations on Filamin A Binding and Localization of Midbody Markers
(A) Disruption of the Filamin A interaction with BRCA2 by BRCA2mutations shown by immunoblot (WB) for BRCA2 and Filamin A in anti-FLAG IPs from 293T cells
expressing FLAG-tagged wild-type (WT-B2) or missense mutants of BRCA2.
(B) Absence of BRCA2mutants from themidbody shown by direct visualization of GFP-tagged BRCA2 and by IF for FLAG (green) and a-tubulin (red) in 293T cells
expressing FLAG-tagged WT or mutant BRCA2.
(C) Disruption of midbody marker localization by E3002K and R3005A shown by IF of 293T cells expressing mutant BRCA2 for midbody markers (green) and
a-tubulin (red).
(D) Reconstitution of midbody components by E3002K and R3005A in brca2/ cells shown by IF of brca2/ cells expressingmutant BRCA2 for a-tubulin (green)
andMKLP1 or Endobrevin (green). Arrows indicate absence of BRCA2 protein (B) and disruption of midbody markers (C and D). Scale bars represent 5 mm (B–D).
See also Figure S5 and Movie S6.
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Figure 5. Association of BRCA2 Mutations with Cytokinetic but Not DNA Repair Defects
(A) Percent of 293T cells (n = 200) with multiple nuclei (multinucleated) and unresolved cytokinetic bridges 72 hr after expression of wild-type (WT) and missense
mutants of BRCA2.
(B and C) Percent of brca2+/+ (n = 200) (B) or brca2/ (n = 200) (C) cells with multiple nuclei and unresolved cytokinetic bridges 72 hr after expression of E3002K
and R3005A mutants.
(D) Percent polyploidy of brca2+/+ and brca2/ cells inmetaphase spreads (n = 50), 72 hr after expression of wild-type (WT) E3002K or R3005ABRCA2. Error bars
represent SE (A–D).
(E) Rescue of homologous directed repair activity by BRCA2 mutants in brca2-deficient DR-GFP V-C8 cells. Fold increase in GFP positive cells relative to vector
identified by FACS analysis following cotransfection with I-Sce1 and WT or mutant BRCA2 constructs.
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Figure 6. Influence of BRCA2 on CEP55-Alix and CEP55-Tsg101 Complex Formation
(A) In vitro binding of His-tagged CEP55 and His-tagged EABR-CEP55 to GST-tagged fragments of BRCA2 shown by WB for CEP55, His-tag and GST;
Coomassie stained gels show bacterially expressed BRCA2 fragments. GST-TP53 is a negative control.
(B) Influence of BRCA2 loss on CEP55-Alix and CEP55-Tsg101 complexes. Immunoblot (WB) for CEP55, Alix, and Tsg101 in endogenous CEP55 immuno-
precipitates (IPs) from brca2+/+ and brca2/ cells and 293T cells treated with control or BRCA2 siRNA. Whole cell lysates (WCL) are shown as controls.
(C) Identification of the CEP55, Alix, and Tsg101 interacting domains of BRCA2 by WB of anti-FLAG IPs from 293T cells expressing FLAG-tagged fragments
of BRCA2.
(D) Fine-mapping of Alix and CEP55 interacting domains of BRCA2; GFP, CEP55, and Alix WB of anti-GFP IPs from late mitotic 293T cells expressing EGFP-
tagged WT and internal deletion mutants (shown in schematic) of a BRCA2 N-terminal fragment (aa 1–815).
(E) Effect of BRCA2 missense mutations on the BRCA2 interactions with CEP55, Alix, and Tsg101; BRCA2, CEP55, Alix, and Tsg101 WB of anti-FLAG IPs from
late mitotic 293T cells expressing FLAG-tagged full-length WT and missense mutants of BRCA2 (as indicated).
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that BRCA2 interacts with CEP55 (Figure 1D), a midbody
component that has been implicated in the formation of the mid-
body ring (Zhao et al., 2006) and localization of ESCRT
complexes to the midbody through interactions with Alix and
Tsg101 (Carlton and Martin-Serrano, 2007; Morita et al., 2007).
Immunoprecipitation and western blotting were subsequently
used to confirm interactions between ectopically expressed
BRCA2 and CEP55 (Figure S6A) and to show that BRCA2 also
formed complexes with Alix and Tsg101 in cells aligned in
mitosis (Figure S6B). Next we established that recombinant
GST-tagged BRCA2 fragment F2 (amino acids 421–982) directly
bound to recombinant His-tagged full-length CEP55 (Figure 6A)
and to a fragment of CEP55 (amino acids 160–217) containing
the ESCRT- and Alix-binding region (EABR) (Figure 6A). Given
this interaction between BRCA2 and the CEP55 EABR domain,
we explored the influence of BRCA2 on the formation of
CEP55-Alix and CEP55-Tsg101 complexes. CEP55 interactions
with Alix and Tsg101 were substantially reduced in brca2/
cells relative to brca2+/+ tumor cells, and in BRCA2-depleted
293T cells relative to controls (Figure 6B), suggesting a role for
BRCA2 in the formation of these complexes.
Fine mapping of the regions of BRCA2 involved in the interac-
tions was undertaken to gain further insight into the composition
of the complexes. Immunoprecipitation of BRCA2 fragments
showed that CEP55, Alix and Tsg101 all interacted with
BRCA2-F2 (amino acids 271–552) and BRCA2-F3 (amino acids
522–836) (Figure 6C). Further mapping of the interactions of
CEP55 and Alix with an N-terminal BRCA2 fragment (amino
acids 1–815) containing eight different100 amino acid in-frame
deletions in 293T cells synchronized in late mitosis (Figure 6D)
found that amino acids 574–675 (Mut-7) of BRCA2were required
for interactions with both CEP55 and Alix. In addition, amino
acids 203–300 (Mut-4) were necessary for the interaction with
Alix, whereas amino acids 447–575 (Mut-6) were only necessary
for the CEP55 interaction (Figure 6D), suggesting complex inter-
actions between these proteins possibly involving independent
binding sites. In keeping with these results, we found that Alix
had different binding sites for CEP55 and BRCA2 in cells
synchronized during mitosis (Figure S6C). Specifically, amino
acids 101–296 of Alix (Del-2 and Del-3) were required for the
Alix interaction with BRCA2, whereas amino acids 709–800 con-
taining a previously defined CEP55 binding site (Lee et al., 2008),
as well as amino acids 101–296, were required for the Alix-
CEP55 interaction (Figure S6C). Because BRCA2 can interact
with Alix in the absence of amino acids 709–800, it appeared
that BRCA2 forms complexes with Alix during mitosis indepen-
dently of the Alix interaction with CEP55.
To confirm these results we evaluated the influence of a series
of breast cancer associated missense mutations from the N
terminus of BRCA2 on BRCA2 interactions with CEP55, Alix,
and Tsg101 (Figure 6E). The mutations were selected because
they altered amino acids displaying evolutionary conservation(F) WB (as shown) of IPs, IP supernatants, and anti-Alix secondary-IP of CEP55 an
late mitosis. Sup, supernatant; I-CEP55, CEP55 immunodepleted supernatant; I
(G) Disruption of CEP55-Alix and CEP55-Tsg101 complexes by BRCA2mutations
transfection with vector, wild-type (WT-B2), or indicated mutant BRCA2 constru
See also Figure S6.
Devefrom sea urchin to human and were considered likely to alter
protein function. T582P disrupted interaction with all three part-
ners (Figure 6E). The N277Kmutant interacted with Alix but failed
to interact with CEP55, consistent with the inability of Mut-4
(amino acids 203–300) to interact with CEP55 (Figure 6E). In
contrast, C554W reduced the BRCA2 interaction with Alix and
Tsg101 but had no influence of the interaction with CEP55 (Fig-
ure 6E), consistent with the effect of Mut-6 (amino acids 447–
575) (Figure 6D). Separately, I488R only impaired the Tsg101
interaction with BRCA2. These findings suggested that BRCA2
has the ability to independently interact with CEP55, Alix, and
Tsg101 during mitosis. To further evaluate this possibility we
conducted a series of immunodepletion studies. Specifically,
we depleted CEP55 and BRCA2 by immunoprecipitation from
HeLa cells synchronized in late mitosis (Figure 6F, lanes 1–6)
and assessed the ability of Alix to coimmunoprecipitate with
BRCA2, CEP55, and Tsg101 in the cleared supernatants (Fig-
ure 6F, lanes 7 and 8). Immunoblot analysis revealed that Alix
formed a complex with BRCA2 when CEP55 was depleted (Fig-
ure 6F, lane 7) and that Alix interacted with CEP55 when BRCA2
was depleted (Figure 6F, lane 8), suggesting that once these
proteins have been recruited to the midbody, removal of certain
components (by immunodepletion) does not influence complex
formation. In contrast, depletion of CEP55 by siRNAs inhibits
formation of BRCA2-Alix and BRCA2-Tsg101 complexes (Fig-
ure S6D) and BRCA2 depletion by siRNA inhibits formation of
CEP55-Alix and CEP55-Tsg101 complexes (Figure 6B) because
Alix and Tsg101 cannot be recruited to the disrupted midbody
(Zhao et al., 2006). These findings suggest that BRCA2 can
interact with Alix independently of CEP55 or Tsg101 and vice
versa at the midbody during cytokinesis.
BRCA2 Interaction Influences Midbody Localization of
Alix and Tsg101
Because BRCA2 colocalizes with CEP55, Alix, and Tsg101 at the
midbody (Figure 2A) we evaluated whether localization of
BRCA2 to the midbody influenced BRCA2 and CEP55
complexes involving Alix and Tsg101. In addition to T582P,
which disrupts the BRCA2 interaction with CEP55, we tested
the effect of E3002K and R3005A mutations that impaired Fila-
min A dependent midbody localization of BRCA2 on formation
of these complexes. Similarly to the N-terminal T582P mutant,
the BRCA2 E3002K and R3005A mutants substantially inhibited
BRCA2 interaction with CEP55, Alix, and Tsg101 and also
CEP55 interaction with Alix and Tsg101 (Figure 6G). Interest-
ingly, this suggests that the BRCA2-Alix interaction observed
in the absence of CEP55 (Figure 6F) is dependent on localization
of BRCA2 to the midbody.
Next, we used immunofluorescence staining of 293T cells ex-
pressing BRCA2 mutants to test whether the interactions of
BRCA2 with CEP55, Alix, and Tsg101 influenced the midbody
localization of these proteins. The E3002K and R3005A mutants
from the Filamin A interacting domain, that failed to localize to thed BRCA2 (B2) immunodepleted supernatants from HeLa cells synchronized in
-BRCA2, BRCA2 immunodepleted supernatant.
. WB (as shown) of Myc or BRCA2 IPs from synchronized 293T cells, 48 hr after
cts in combination with Myc-tagged CEP55.
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Figure 7. Effect of BRCA2 Mutation on Alix and Tsg101 Localization and Cytokinesis
(A) Summary of midbody localization of BRCA2, Alix, and Tsg101 in response to BRCA2 missense mutants. +, normal; –, reduced localization.
(B and C) Disruption of Alix (B) and Tsg101 (C) midbody localization by BRCA2 mutations shown by immunofluorescence (IF) staining for Alix and Tsg101 in 293T
cells expressing FLAG or GFP-tagged WT and mutant BRCA2. Arrows indicate midbodies. Scale bars represent 5 mm.
(D and E) Bar graph of percent 293T cells with multiple nuclei and unresolved cytokinetic bridges 72 hr after transfection with the indicated BRCA2 constructs;
p-values (E) indicate the statistical significance of the differences.
(F) Rescue of homology directed repair activity of BRCA2 mutants in brca2-deficient DR-GFP V-C8 cells. GFP positive cells were identified by FACS analysis
following cotransfection with I-Sce1 and WT or mutant BRCA2 vectors. Error bars represent SEM (D–F).
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the midbody (Figures 7A–7C). Similarly, the C554W and T582P
mutants that perturbed the BRCA2 interactions with Alix and
Tsg101 diminished the levels of Alix and Tsg101 at the midbody,
but did not influence localization of BRCA2 (Figure 7A) or Plk1,
MKLP1, or PRC1 to the midbody (Figures S7A and S7B). In addi-
tion, theN277Kmutation that only influenced the BRCA2 interac-
tion with CEP55 and Tsg101 (Figure 6E), reduced localization of
Tsg101 to themidbody but had no effect on Alix localization (Fig-
ure 7A). In all cases, no effect on CEP55 localization to the mid-
body was observed, consistent with our finding that depletion of
BRCA2 did not influence the midbody localization of CEP55
(Figures 2A and 2B) and that depletion of CEP55 had no effect
on BRCA2 localization to the midbody (Figures S7C and S7D).
Together these results indicate that individual interactions of
BRCA2 with CEP55, Alix and Tsg101 during cytokinesis are
important for recruitment of ESCRT-associated and ESCRT
complexes to the midbody.
BRCA2 Interaction with CEP55, Alix, and Tsg101
Regulates Cytokinesis
Previously we showed that missense mutations in the Filamin A
interacting domain of BRCA2 reduced the efficiency of BRCA2
localization to the midbody and caused an increase in cyto-
kinesis defects (Figures 4B and 5A–5D). Here we evaluated the
influence of the missense mutations in the N-terminal domain
of BRCA2 that disrupted interactions with CEP55, Alix, and
Tsg101 on the integrity of cytokinesis (Figure 7D). The N277K,
I488R, and C554Wmutants, which disrupted complex formation
and localization of Alix or Tsg101 to the midbody, all increased
the frequency of multinucleation and delayed cytokinetic bridge
resolution relative to wild-type BRCA2 (Figure 7D). Likewise the
T582P mutant that reduced the interactions with CEP55, Alix,
and Tsg101caused a significant difference in the frequency of
multinucleation (p = 0.006) and unresolved cytokinetic bridges
(p = 0.024) relative to wild-type BRCA2 (WT-BRCA2) (Figures
7D and 7E). Importantly, T582P did not influence BRCA2
homology directed repair activity (Figure 7F). Furthermore, like
wild-type and the E3002K mutant, the T582P mutant partially
rescued localization of Myosin II to the cortex of BRCA2-defi-
cient PEO1 cells during furrow ingression (Figure S7E) and did
not disruptMyosin II localization to the cleavage furrow or central
spindle in 293T cells (Figure S7E). Thus, disruption of the BRCA2
interaction with CEP55 or the downstream components Alix and
Tsg101 appears to directly influence the terminal stage of cyto-
kinesis but has no effect on HDR activity or Myosin II associated
furrow formation.
DISCUSSION
Several lines of evidence suggest that BRCA2 has a role in
regulation of cytokinesis. Both normal and malignant BRCA2-
deficient cells exhibit numerical chromosomal abnormalities(G) Model of BRCA2 activity at the midbody. Stages of progression from anaphas
BRCA2 is recruited to the midbody by Filamin A during furrow ingression and c
of CEP55-Alix and CEP55-Tsg101 complexes. Impairment of BRCA2 function re
or failed cytokinesis.
See also Figure S7.
Deveoften in the form of polyploidy, and both depletion and inactiva-
tion of BRCA2 is associated with an accumulation of 4N cells
(Daniels et al., 2004; Jonsdottir et al., 2009), consistent with
a failure of cytokinesis. Here we confirm that BRCA2 accumu-
lates at the midbody, regulates midbody structure and function,
and regulates the efficiency of cytokinesis, independently of
DNA damage repair. Specifically, we detected both endogenous
BRCA2 and FLAG-tagged versions of BRCA2 in HeLa cells, and
demonstrated reconstitution of BRCA2 to the midbody in
brca2/ murine pancreatic tumor cells and BRCA2-deficient
PEO1 human ovarian cancer cells. We also used reconstitution
and live cell confocal imaging experiments to establish that
BRCA2 is involved in regulation of cytokinesis. Furthermore,
we established that the recruitment of BRCA2 to the central
spindle and the midbody is dependent on an interaction with
Filamin A, a component of actomyosin complexes (Figure 7G).
Our data suggest that inactivation or loss of BRCA2 from the
midbody disrupts recruitment of specific markers to the mid-
body. Moreover, we show that BRCA2 regulates the recruitment
of Alix and Tsg101 to the midbody and the formation of CEP55-
Alix and CEP55-Tsg101 complexes that are required for recruit-
ment of ESCRT complexes and subsequent cell separation
(Figure 7G). Overall, although the effect of BRCA2 depletion is
not as severe as depletion of essential structural components
of the midbody such as MKLP1 or CEP55 (Matuliene and Kur-
iyama, 2002; Morita et al., 2007), BRCA2 appears to play an
important role in regulation of final abscission by mediating the
assembly of a number of midbody factors and signaling compo-
nents (Figures 2A and 2B). These results are consistent with
previous studies suggesting that BRCA2 influences the midbody
(Daniels et al., 2004; Jonsdottir et al., 2009) but contrast with
results from a recent study by Lekomtsev et al. (2010) that sug-
gested that BRCA2 did not localize to the cytokinetic bridge and
had no influence on cytokinesis. The absence of data supporting
the influence of BRCA2 on the midbody and cytokinesis may
have resulted from the use of a limited set of antibodies and
siRNAs. Importantly, the Lekomtsev et al. (2010) findings also
contrast with those from a recent study showing that HMG20b,
a kinesin-like coiled coil protein, interacts with BRCA2 BRC5
and influences the completion of cell division, but does not influ-
ence BRCA2-Rad51 interactions or BRCA2 DNA repair activity
(Lee et al., 2011). Filamin A, an actin binding protein that can
act as a scaffold for numerous proteins has been detected at
the midbody (Feng and Walsh, 2004; Nunnally et al., 1980) and
has been implicated in regulation of cytokinesis (Playford et al.,
2006). Here, we demonstrate that disruption of the Filamin A-
BRCA2 interaction is sufficient to exclude BRCA2 from the mid-
body, to disrupt the localization of midbody markers, and to
substantially increase the proportion of cells that exhibit delay
or failure of cytokinesis. In addition, we show that depletion of
BRCA2 or disruption of the BRCA2 interaction with Filamin A
has no effect on Filamin A localization at the midbody, suggest-
ing that BRCA2 functions downstream of Filamin A duringe through completion of cytokinesis are shown by a-tubulin and DAPI staining.
ytokinetic bridge formation, and interacts with CEP55 to assist the formation
duces the availability of these complexes at the midbody leading to abnormal
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A-dependent recruitment of BRCA2 to the central spindle and
midbody in the maintenance of cytokinesis (Figure 7G).
In this study, we report that BRCA2 is required for normal
positioning of a number of important regulators of cytokinesis,
including PRC1, MKLP1, and MKLP2, at the midbody during
abscission. In particular, in the absence of BRCA2, the PRC1
marker of the central spindle and midbody (Kurasawa et al.,
2004) was dispersed along the microtubules on the cytokinetic
bridge during late abscission. PRC1 is required for recruitment
of MKLP1 and MgcRacGAP (centralspindlin) to the central
spindle and depletion of PRC1 results in the absence of central-
spindlin from the central spindle and failure of abscission (Molli-
nari et al., 2005). However, PRC1 mislocalization due to BRCA2
deficiency did not displace MgcRacGAP or MKLP1 from the
central spindle. Instead the effect on PRC1 appears to be
restricted to efficient recruitment and/or retention of PRC1 at
the midbody after successful recruitment of MgcRacGAP and
MKLP1 to the central spindle. This finding is reminiscent of
the dispersion of PRC1 along the cytokinetic bridge and the
failure of abscission observed after CEP55 depletion (Fabbro
et al., 2005; Zhao et al., 2006). Furthermore, although the
MKLP1 and MKLP2 microtubule-associated proteins were effi-
ciently recruited to the central spindle and midbody during
abscission in BRCA2-deficient cells, these kinesins displayed
disordered positioning at the midbody ring (Figures 2A and
2B), a tubulin enriched structure decorated by the centralspindlin
complex, MKLP2, and CEP55 that forms in late telophase in the
phase-dense Flemming body (Gromley et al., 2005). This struc-
ture is thought to function as a docking site for machinery
involved in membrane fusion during late abscission, including
SNARE and ESCRT complexes (Prekeris and Gould, 2008).
Because we show that BRCA2 interacts with CEP55, influences
MKLP1 and MKLP2 positioning, and disrupts recruitment of
ESCRT complexes to the midbody, the suggestion is that
BRCA2 is an important regulator of the structure and function
of the midbody ring.
Dimeric CEP55 localizes to the central spindle and midbody
during cytokinesis, possibly through direct binding to MKLP1,
where it influences the establishment and proper function of
the midbody structure (Lee et al., 2008). In addition, CEP55 is
required for membrane fusion at the terminal stage of cytokinesis
through direct recruitment of the ESCRT-1 component, Tsg101,
and the ESCRT-interacting protein Alix to themidbody ring (Carl-
ton and Martin-Serrano, 2007). Disruption of the BRCA2-CEP55
interaction resulted in reduced CEP55-Alix and CEP55-Tsg101
complex formation and reduced levels of Alix, Tsg101, and
Endobrevin at the midbody, consistent with the effects of
CEP55 or BRCA2 depletion (Carlton and Martin-Serrano, 2007;
Zhao et al., 2006). However, in contrast to BRCA2 deficiency,
absence of CEP55 displaced Plk1, Aurora B and MKLP2 from
the midbody, consistent with reports of complete absence of
the Flemming body from themidbody following CEP55 depletion
(Zhao et al., 2006). Because CEP55 depletion had a greater
effect on the midbody than exclusion of BRCA2 from the mid-
body or disruption of CEP55-BRCA2 complexes, we speculate
that BRCA2 regulates a subset of CEP55 signaling pathways
in the midbody, including CEP55 interactions with membrane
sorting complexes.150 Developmental Cell 23, 137–152, July 17, 2012 ª2012 Elsevier InIt has been shown that CEP55 interactions with Alix and
Tsg101 through the EABR domain can be regulated by other
binding partners, such as Tex14, which competes with Alix
and Tsg101 for binding to CEP55 at the midbody and prevents
completion of cytokinesis in germ cells (Iwamori et al., 2010).
Given that BRCA2 also interacts with CEP55 through the EABR
domain and is required for cytokinesis, we evaluated whether
BRCA2 influences CEP55 complex formation and functions as
a scaffold for assembly of protein complexes at the midbody.
Depletion of CEP55 by siRNAs disrupted the interaction between
BRCA2 and Alix in mitotic cells. However, we successfully iden-
tified Alix-BRCA2 complexes after CEP55 immunodepletion
from cells aligned in mitosis (Figure 6F), when BRCA2 and Alix
were already present at the midbody. Similarly, depletion of
BRCA2 disrupted formation of CEP55-Alix complexes, whereas
immunodepletion of BRCA2 during cytokinesis after recruitment
of Alix to the midbody had no effect on CEP55-Alix complex
formation. We also showed that BRCA2 interacted with Alix
through a CEP55-independent binding site (Figures 6D and 6E)
and that disruption of BRCA2 binding sites in Alix (amino acids
101–209 and 216–296) interfered with the interaction between
Alix and CEP55, despite the continued presence of a CEP55
binding site (amino acid region 709–800) in the mutant Alix
protein. Together these data suggest that the presence of
BRCA2 at the midbody is required for efficient recruitment of
Alix, Tsg101 and ESCRT complexes to the midbody, consistent
with a scaffolding activity. Although it is intriguing to speculate
that CEP55, Alix and Tsg101 all interact with BRCA2 in the mid-
body and that BRCA2 promotes the interaction of Alix and
Tsg101 with CEP55 through the CEP55 EABR domain, this
model does not appear to be consistent with recent studies
showing direct binding of Alix and Tsg101 to CEP55 in vitro in
the absence of BRCA2 (Lee et al., 2008). However, it is possible
that BRCA2 recruits and delivers Alix and Tsg101 to CEP55
in vivo by binding to CEP55 EABR and facilitates loading of
Alix and Tsg101 onto CEP55 by exchange of binding to the
EABR site. This recruitment and loading activity would not be
observed in an in vitro binding model in the presence of excess
protein. Alternatively, BRCA2 may protect CEP55 from Tex14
binding at the EABR domain or may displace Tex14 from the
EABR domain, thereby facilitating completion of abscission.
Further studies are needed to resolve the mechanism by which
BRCA2 influences CEP55-associated recruitment of ESCRT
complexes to the midbody (Figure 7G).
The contribution of BRCA2 to homologous recombination
repair of DNA double strand breaks has been well documented
(Wu et al., 2005; Yang et al., 2002). Given recent evidence that
unresolved chromatin in cytokinetic bridges can result in delays
and failure of abscission and cytokinesis (Steigemann et al.,
2009), the possibility existed that impaired DNA repair activity
in the absence of BRCA2 also accounted for the observed cyto-
kinetic defects. Here we provide evidence that regulation of
cytokinesis by BRCA2 is independent of the established DNA
repair activity of the protein by showing that Lap2b stained unre-
solved DNA strands or BLM stained UFBs were not present at
increased frequency in BRCA2-deficient or mutant cells relative
to wild-type controls. Thus, the failure of cytokinesis due to in-
active BRCA2 is at least in part independent of defects in DNA
decatenation or sister chromatid separation. In addition, wec.
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gene, deficient in HDR activity due to the absence of a large part
of the BRCA2 DNA-binding domain, efficiently reduced the
frequency of cytokinesis defects (Figure S1O), suggesting
an HDR-independent role for BRCA2 in regulation of cytokinesis.
Furthermore, we used missense mutations in the Filamin A inter-
acting domain of BRCA2 to distinguish between the ability of
BRCA2 to mediate DNA repair and cytokinesis. We found that
the E3002K mutation that disrupted the BRCA2 interaction
with Filamin A and induced a failure of cytokinesis also inhibited
the homologous recombination activity of BRCA2 (Farrugia et al.,
2008; Wu et al., 2005). Importantly the E3002K mutation may
disrupt predicted hydrogen bonding and van der Waal’s interac-
tions at the interface between the OB1 and OB2 domains in
the crystal structure of rat BRCA2 leading to structural alter-
ations and inactivation of all BRCA2 functions involving this
region of BRCA2. In contrast, the R3005A mutation, which also
disrupted Filamin A binding and cytokinesis, had no effect on
homologous recombination. This is consistent with the crystal
structure based finding that Filamin A interacting residues in
BRCA2 are distinct from the major DNA binding and DSS1
binding residues in the same region (Yang et al., 2002). Thus,
R3005A may only influence Filamin A binding whereas E3002K
may induce a more significant conformational change in this
region of BRCA2 resulting in disruption of both Filamin A and
DNA binding. Similarly, the T582P mutation, that had no effect
on localization of BRCA2 to the centrosome and midbody, but
was associated with reduced binding to CEP55, Alix and
Tsg101 and a significantly increased frequency of cytokinetic
defects, displayed wild-type BRCA2 HDR activity. Thus, these
missense mutations effectively distinguish between the con-
tributions of BRCA2 to HR DNA repair and cytokinesis and
suggest a direct role for BRCA2 at the midbody in regulation of
cytokinesis. Whether the specific defects in cytokinesis influ-
ence cancer risk and/or promote tumor progression remains to
be determined.
In conclusion, we show that BRCA2 plays an important role
in regulation of cytokinesis by mediating the assembly of factors
at the midbody. Thus, the delays or failure of cytokinesis associ-
ated with BRCA2 mutation may account in part for the numerical
chromosomal defects in BRCA2mutant cells andmay contribute
to the development of cancer in BRCA2 mutation carriers.
EXPERIMENTAL PROCEDURES
Detailed descriptions of all experimental methods are provided in the Supple-
mental Experimental Procedures.
Plasmid Construction
FLAG-tagged full-length BRCA2 (WT-BRCA2) and fragments of BRCA2 were
cloned into the pcDNA3.1 vector. Point mutants of BRCA2 were generated
using the Quikchange site-directed mutagenesis kit (Stratagene). EGFP-
BRCA2 was cloned in pEGFP-C2 vector (Clonetech).
Live-Cell Imaging
Live cell imaging was performed using brca2+/+ and brca2/ mouse tumor
cells and HeLa cells transiently transfected with BRCA2 siRNA (Dharmacon
and QIAGEN), CEP55 siRNAs (IDT), or BRCA2 siRNAs and the GFP-tagged
BRCA2 mini-gene. BRCA2 localization studies were also conducted by live
cell imaging of 293T cells transfected with mCherry tagged a-tubulin and
GFP-tagged BRCA2 using a Zeiss LSM510 confocal microscope.DeveHomologous Recombination Repair Assay
The homologous recombination repair assay was carried out as described
previously (Wu et al., 2005).
Quantitation and Statistical Analysis of Immunofluorescence and
Live-Cell Imaging Data
To compare the relative counts of the numbers of cells displaying categorized
phenotypes (normal, delayed cytokinesis, or failed cytokinesis) (Figure 1),
(Lap2b positive versus negative) (Figure S2), (MKLP1, MKLP2, and PRC1
localized or mislocalized) (Figure 2), (present or absent of Endobrevin) or
(prominent, weak, absence of Alix and Tsg101) (Figure 2) between different
cell types in each experiment we applied a Poisson regression approach
(McCullagh and Nelder, 1989) implemented in SAS (SAS Institute, Cary, NC).
A separate Poisson regression model was fit to the observed data for each
specific comparison.
SUPPLEMENTAL INFORMATION
Supplemental Information includes seven figures, Supplemental Experimental
Procedures, and six movies and can be found with this article online at
http://dx.doi.org/10.1016/j.devcel.2012.05.008.
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